Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech/OSI Touting Tarceva Pancreatic Cancer Overall Survival Benefit

Executive Summary

Genentech and marketing partner OSI are highlighting the overall survival benefit of combination use with Tarceva over gemcitabine (Lilly's Gemzar) plus placebo for treatment of advanced pancreatic cancer

You may also be interested in...



Pfizer’s Axitinib May Have Survival Benefit Over Tarceva In Pancreatic Cancer

Pfizer's oral selective VEGF inhibitor axitinib in combination with standard chemotherapy improves overall survival by 1.3 months and decreased the risk of death by 33 percent compared to standard care in advanced pancreatic cancer patients, the firm reported during a June 4 presentation at the American Society of Clinical Oncology meeting in Chicago

Pfizer’s Axitinib May Have Survival Benefit Over Tarceva In Pancreatic Cancer

Pfizer's oral selective VEGF inhibitor axitinib in combination with standard chemotherapy improves overall survival by 1.3 months and decreased the risk of death by 33 percent compared to standard care in advanced pancreatic cancer patients, the firm reported during a June 4 presentation at the American Society of Clinical Oncology meeting in Chicago

Roche Keeps Lifecycle Management In Motion For Oncology Portfolio

The potential near-term approval of Roche/Genentech's Herceptin (trastuzumab) for adjuvant treatment of early-stage, HER2-positive breast cancer is one of several line extensions under the firms' aggressive lifecycle management of their partnered oncologics

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS046519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel